In the company’s news Friday,
Memory Pharmaceuticals Corp. announced the completion of its phase I multiple ascending dose study of R4996/MEM 63908. The study is the fourth and final study involving health volunteers to determine the efficacy of the nicotinic alpha-7 receptor being developed in collaboration with Roche.
Per the agreement, Memory Pharmaceuticals is responsible for conducting the clinical trials, while Roche is responsible for later-stage development and commercialization.
“We conducted a robust and comprehensive phase 1 program for R4996/MEM 63908, during which over 100 volunteers took R4996/MEM 63908. The data from these studies will provide us and our partner Roche with important insights into the safety, dosing and appropriate development path for the compound,” Stephen Murray, M.D., Ph.D., chief medical officer of Memory Pharmaceuticals, stated in the press release. “R4996/MEM 63908, the second compound in our nicotinic alpha-7 receptor program, has the potential to address serious cognitive disorders such as Alzheimer’s disease, and we look forward to analyzing the data from these studies.”
The study included a randomized, double-blind, placebo-controlled single ascending dose study in 56 healthy adult male volunteers; a food interaction study in 12 healthy adult male volunteers; a randomized, placebo-controlled single dose study in 16 elderly male and female volunteers; and a randomized, placebo-controlled multiple ascending dose study in 48 healthy volunteers, which included 32 young males and females and 16 elderly males and females.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
